Subcutaneous Panniculitis-like T-cell Lymphoma: Immunosuppressive Drugs Induce Better Response than Polychemotherapy
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare condition usually considered to have a favourable prognosis. However, it is not known whether polychemotherapy or immunosuppressive-based therapy is the best approach for treating SPTCL. Using data collected between 2000 and 2012 in Fr...
Gespeichert in:
| Veröffentlicht in: | Acta dermato-venereologica 2017-03, Vol.97 (3), p.358-364 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 364 |
|---|---|
| container_issue | 3 |
| container_start_page | 358 |
| container_title | Acta dermato-venereologica |
| container_volume | 97 |
| creator | Michonneau, David Petrella, Tony Ortonne, Nicolas Ingen-Housz-Oro, Saskia Franck, Nathalie Barete, Stéphane Battistella, Maxime Beylot-Barry, Marie Vergier, Béatrice Maynadié, Marc Bodemer, Christine Hermine, Olivier Bagot, Martine Brousse, Nicole Fraitag, Sylvie |
| description | Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare condition usually considered to have a favourable prognosis. However, it is not known whether polychemotherapy or immunosuppressive-based therapy is the best approach for treating SPTCL. Using data collected between 2000 and 2012 in France, we analysed clinical, biological and pathological data of 27 patients with SPTCL. Medical history revealed that 40% of patients had been previously diagnosed with an autoimmune disorder and 22% with inflammatory panniculitis. Haemophagocytic syndrome was present in 37% of cases. Autoantibodies were positive in 65% of cases. Complete remission (CR) was reached in 74% of cases. Immunosuppressive drug treatment was given in 69.5% of patients (group 1) and polychemotherapy in 30.5% (group 2). CR was 81.2% and 28.5% (p?=?0.025), respectively. Progression rate was 6.2% and 42.8% (p?=?0.067), respectively. This study suggests that immunosuppressive drugs should be considered as the first-line treatment for SPTCL. |
| doi_str_mv | 10.2340/00015555-2543 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01516926v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1835399838</sourcerecordid><originalsourceid>FETCH-LOGICAL-c366t-35becba4bc912ea65c06e0f1970ddafed265783ea59fc0f4d5c9ecf0f414cc243</originalsourceid><addsrcrecordid>eNo9kctP3DAQxq0KVJYtx16Rj3Bw8SN2kt4olLLSSqwonC3HmTShSZz6gbT_fRMtMJd5_fRJMx9CXxn9xkVGryilTM5BuMzEJ7RiSjLCqcyP0GrZkWV5gk5DeJlbLlnxGZ3wPOc8V9kKxd-psimaEVwKeGfGsbOp72IXSN_9BfxELPQ93u6HqXWD-Y43w5BGF9I0eQihewV869OfgDdjnSzgHxAjePwIYXJjABxbM-Kd6_e2hcHFFryZ9l_QcWP6AGdveY2e734-3dyT7cOvzc31llihVCRCVmArk1W2ZByMkpYqoA0rc1rXpoGaK5kXAowsG0ubrJa2BNvMFcus5ZlYo8uDbmt6PfluMH6vnen0_fVWL7P5dUyVXL2ymb04sJN3_xKEqIcuLLcfXqNZIaQoy0IUM0oOqPUuBA_NhzajejFFv5uiF1Nm_vxNOlUD1B_0uwviP095iR0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835399838</pqid></control><display><type>article</type><title>Subcutaneous Panniculitis-like T-cell Lymphoma: Immunosuppressive Drugs Induce Better Response than Polychemotherapy</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>IngentaConnect Free/Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Michonneau, David ; Petrella, Tony ; Ortonne, Nicolas ; Ingen-Housz-Oro, Saskia ; Franck, Nathalie ; Barete, Stéphane ; Battistella, Maxime ; Beylot-Barry, Marie ; Vergier, Béatrice ; Maynadié, Marc ; Bodemer, Christine ; Hermine, Olivier ; Bagot, Martine ; Brousse, Nicole ; Fraitag, Sylvie</creator><creatorcontrib>Michonneau, David ; Petrella, Tony ; Ortonne, Nicolas ; Ingen-Housz-Oro, Saskia ; Franck, Nathalie ; Barete, Stéphane ; Battistella, Maxime ; Beylot-Barry, Marie ; Vergier, Béatrice ; Maynadié, Marc ; Bodemer, Christine ; Hermine, Olivier ; Bagot, Martine ; Brousse, Nicole ; Fraitag, Sylvie</creatorcontrib><description>Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare condition usually considered to have a favourable prognosis. However, it is not known whether polychemotherapy or immunosuppressive-based therapy is the best approach for treating SPTCL. Using data collected between 2000 and 2012 in France, we analysed clinical, biological and pathological data of 27 patients with SPTCL. Medical history revealed that 40% of patients had been previously diagnosed with an autoimmune disorder and 22% with inflammatory panniculitis. Haemophagocytic syndrome was present in 37% of cases. Autoantibodies were positive in 65% of cases. Complete remission (CR) was reached in 74% of cases. Immunosuppressive drug treatment was given in 69.5% of patients (group 1) and polychemotherapy in 30.5% (group 2). CR was 81.2% and 28.5% (p?=?0.025), respectively. Progression rate was 6.2% and 42.8% (p?=?0.067), respectively. This study suggests that immunosuppressive drugs should be considered as the first-line treatment for SPTCL.</description><identifier>ISSN: 0001-5555</identifier><identifier>EISSN: 1651-2057</identifier><identifier>DOI: 10.2340/00015555-2543</identifier><identifier>PMID: 27722764</identifier><language>eng</language><publisher>Sweden: Society for Publication of Acta Dermato-Venereologica</publisher><subject>Adolescent ; Adult ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biopsy ; Cancer ; Child ; Child, Preschool ; Dermatology ; Disease Progression ; Female ; France ; Human health and pathology ; Humans ; Immunology ; Immunosuppressive Agents - adverse effects ; Immunosuppressive Agents - therapeutic use ; Immunotherapy ; Infant ; Life Sciences ; Lymphoma, T-Cell - drug therapy ; Lymphoma, T-Cell - immunology ; Lymphoma, T-Cell - mortality ; Lymphoma, T-Cell - pathology ; Male ; Middle Aged ; Panniculitis - drug therapy ; Panniculitis - immunology ; Panniculitis - mortality ; Panniculitis - pathology ; Proportional Hazards Models ; Remission Induction ; Retrospective Studies ; Time Factors ; Treatment Outcome ; Young Adult</subject><ispartof>Acta dermato-venereologica, 2017-03, Vol.97 (3), p.358-364</ispartof><rights>Attribution</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c366t-35becba4bc912ea65c06e0f1970ddafed265783ea59fc0f4d5c9ecf0f414cc243</citedby><orcidid>0000-0002-0400-1954 ; 0000-0001-6150-1229 ; 0000-0003-2574-3874 ; 0000-0002-1631-5192 ; 0000-0003-4553-3065 ; 0000-0001-8772-0905 ; 0000-0003-0111-7422</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,860,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27722764$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.sorbonne-universite.fr/hal-01516926$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Michonneau, David</creatorcontrib><creatorcontrib>Petrella, Tony</creatorcontrib><creatorcontrib>Ortonne, Nicolas</creatorcontrib><creatorcontrib>Ingen-Housz-Oro, Saskia</creatorcontrib><creatorcontrib>Franck, Nathalie</creatorcontrib><creatorcontrib>Barete, Stéphane</creatorcontrib><creatorcontrib>Battistella, Maxime</creatorcontrib><creatorcontrib>Beylot-Barry, Marie</creatorcontrib><creatorcontrib>Vergier, Béatrice</creatorcontrib><creatorcontrib>Maynadié, Marc</creatorcontrib><creatorcontrib>Bodemer, Christine</creatorcontrib><creatorcontrib>Hermine, Olivier</creatorcontrib><creatorcontrib>Bagot, Martine</creatorcontrib><creatorcontrib>Brousse, Nicole</creatorcontrib><creatorcontrib>Fraitag, Sylvie</creatorcontrib><title>Subcutaneous Panniculitis-like T-cell Lymphoma: Immunosuppressive Drugs Induce Better Response than Polychemotherapy</title><title>Acta dermato-venereologica</title><addtitle>Acta Derm Venereol</addtitle><description>Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare condition usually considered to have a favourable prognosis. However, it is not known whether polychemotherapy or immunosuppressive-based therapy is the best approach for treating SPTCL. Using data collected between 2000 and 2012 in France, we analysed clinical, biological and pathological data of 27 patients with SPTCL. Medical history revealed that 40% of patients had been previously diagnosed with an autoimmune disorder and 22% with inflammatory panniculitis. Haemophagocytic syndrome was present in 37% of cases. Autoantibodies were positive in 65% of cases. Complete remission (CR) was reached in 74% of cases. Immunosuppressive drug treatment was given in 69.5% of patients (group 1) and polychemotherapy in 30.5% (group 2). CR was 81.2% and 28.5% (p?=?0.025), respectively. Progression rate was 6.2% and 42.8% (p?=?0.067), respectively. This study suggests that immunosuppressive drugs should be considered as the first-line treatment for SPTCL.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biopsy</subject><subject>Cancer</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Dermatology</subject><subject>Disease Progression</subject><subject>Female</subject><subject>France</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Immunology</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Immunotherapy</subject><subject>Infant</subject><subject>Life Sciences</subject><subject>Lymphoma, T-Cell - drug therapy</subject><subject>Lymphoma, T-Cell - immunology</subject><subject>Lymphoma, T-Cell - mortality</subject><subject>Lymphoma, T-Cell - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Panniculitis - drug therapy</subject><subject>Panniculitis - immunology</subject><subject>Panniculitis - mortality</subject><subject>Panniculitis - pathology</subject><subject>Proportional Hazards Models</subject><subject>Remission Induction</subject><subject>Retrospective Studies</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0001-5555</issn><issn>1651-2057</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kctP3DAQxq0KVJYtx16Rj3Bw8SN2kt4olLLSSqwonC3HmTShSZz6gbT_fRMtMJd5_fRJMx9CXxn9xkVGryilTM5BuMzEJ7RiSjLCqcyP0GrZkWV5gk5DeJlbLlnxGZ3wPOc8V9kKxd-psimaEVwKeGfGsbOp72IXSN_9BfxELPQ93u6HqXWD-Y43w5BGF9I0eQihewV869OfgDdjnSzgHxAjePwIYXJjABxbM-Kd6_e2hcHFFryZ9l_QcWP6AGdveY2e734-3dyT7cOvzc31llihVCRCVmArk1W2ZByMkpYqoA0rc1rXpoGaK5kXAowsG0ubrJa2BNvMFcus5ZlYo8uDbmt6PfluMH6vnen0_fVWL7P5dUyVXL2ymb04sJN3_xKEqIcuLLcfXqNZIaQoy0IUM0oOqPUuBA_NhzajejFFv5uiF1Nm_vxNOlUD1B_0uwviP095iR0</recordid><startdate>20170310</startdate><enddate>20170310</enddate><creator>Michonneau, David</creator><creator>Petrella, Tony</creator><creator>Ortonne, Nicolas</creator><creator>Ingen-Housz-Oro, Saskia</creator><creator>Franck, Nathalie</creator><creator>Barete, Stéphane</creator><creator>Battistella, Maxime</creator><creator>Beylot-Barry, Marie</creator><creator>Vergier, Béatrice</creator><creator>Maynadié, Marc</creator><creator>Bodemer, Christine</creator><creator>Hermine, Olivier</creator><creator>Bagot, Martine</creator><creator>Brousse, Nicole</creator><creator>Fraitag, Sylvie</creator><general>Society for Publication of Acta Dermato-Venereologica</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0002-0400-1954</orcidid><orcidid>https://orcid.org/0000-0001-6150-1229</orcidid><orcidid>https://orcid.org/0000-0003-2574-3874</orcidid><orcidid>https://orcid.org/0000-0002-1631-5192</orcidid><orcidid>https://orcid.org/0000-0003-4553-3065</orcidid><orcidid>https://orcid.org/0000-0001-8772-0905</orcidid><orcidid>https://orcid.org/0000-0003-0111-7422</orcidid></search><sort><creationdate>20170310</creationdate><title>Subcutaneous Panniculitis-like T-cell Lymphoma: Immunosuppressive Drugs Induce Better Response than Polychemotherapy</title><author>Michonneau, David ; Petrella, Tony ; Ortonne, Nicolas ; Ingen-Housz-Oro, Saskia ; Franck, Nathalie ; Barete, Stéphane ; Battistella, Maxime ; Beylot-Barry, Marie ; Vergier, Béatrice ; Maynadié, Marc ; Bodemer, Christine ; Hermine, Olivier ; Bagot, Martine ; Brousse, Nicole ; Fraitag, Sylvie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c366t-35becba4bc912ea65c06e0f1970ddafed265783ea59fc0f4d5c9ecf0f414cc243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biopsy</topic><topic>Cancer</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Dermatology</topic><topic>Disease Progression</topic><topic>Female</topic><topic>France</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Immunology</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Immunotherapy</topic><topic>Infant</topic><topic>Life Sciences</topic><topic>Lymphoma, T-Cell - drug therapy</topic><topic>Lymphoma, T-Cell - immunology</topic><topic>Lymphoma, T-Cell - mortality</topic><topic>Lymphoma, T-Cell - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Panniculitis - drug therapy</topic><topic>Panniculitis - immunology</topic><topic>Panniculitis - mortality</topic><topic>Panniculitis - pathology</topic><topic>Proportional Hazards Models</topic><topic>Remission Induction</topic><topic>Retrospective Studies</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Michonneau, David</creatorcontrib><creatorcontrib>Petrella, Tony</creatorcontrib><creatorcontrib>Ortonne, Nicolas</creatorcontrib><creatorcontrib>Ingen-Housz-Oro, Saskia</creatorcontrib><creatorcontrib>Franck, Nathalie</creatorcontrib><creatorcontrib>Barete, Stéphane</creatorcontrib><creatorcontrib>Battistella, Maxime</creatorcontrib><creatorcontrib>Beylot-Barry, Marie</creatorcontrib><creatorcontrib>Vergier, Béatrice</creatorcontrib><creatorcontrib>Maynadié, Marc</creatorcontrib><creatorcontrib>Bodemer, Christine</creatorcontrib><creatorcontrib>Hermine, Olivier</creatorcontrib><creatorcontrib>Bagot, Martine</creatorcontrib><creatorcontrib>Brousse, Nicole</creatorcontrib><creatorcontrib>Fraitag, Sylvie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Acta dermato-venereologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Michonneau, David</au><au>Petrella, Tony</au><au>Ortonne, Nicolas</au><au>Ingen-Housz-Oro, Saskia</au><au>Franck, Nathalie</au><au>Barete, Stéphane</au><au>Battistella, Maxime</au><au>Beylot-Barry, Marie</au><au>Vergier, Béatrice</au><au>Maynadié, Marc</au><au>Bodemer, Christine</au><au>Hermine, Olivier</au><au>Bagot, Martine</au><au>Brousse, Nicole</au><au>Fraitag, Sylvie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Subcutaneous Panniculitis-like T-cell Lymphoma: Immunosuppressive Drugs Induce Better Response than Polychemotherapy</atitle><jtitle>Acta dermato-venereologica</jtitle><addtitle>Acta Derm Venereol</addtitle><date>2017-03-10</date><risdate>2017</risdate><volume>97</volume><issue>3</issue><spage>358</spage><epage>364</epage><pages>358-364</pages><issn>0001-5555</issn><eissn>1651-2057</eissn><abstract>Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare condition usually considered to have a favourable prognosis. However, it is not known whether polychemotherapy or immunosuppressive-based therapy is the best approach for treating SPTCL. Using data collected between 2000 and 2012 in France, we analysed clinical, biological and pathological data of 27 patients with SPTCL. Medical history revealed that 40% of patients had been previously diagnosed with an autoimmune disorder and 22% with inflammatory panniculitis. Haemophagocytic syndrome was present in 37% of cases. Autoantibodies were positive in 65% of cases. Complete remission (CR) was reached in 74% of cases. Immunosuppressive drug treatment was given in 69.5% of patients (group 1) and polychemotherapy in 30.5% (group 2). CR was 81.2% and 28.5% (p?=?0.025), respectively. Progression rate was 6.2% and 42.8% (p?=?0.067), respectively. This study suggests that immunosuppressive drugs should be considered as the first-line treatment for SPTCL.</abstract><cop>Sweden</cop><pub>Society for Publication of Acta Dermato-Venereologica</pub><pmid>27722764</pmid><doi>10.2340/00015555-2543</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-0400-1954</orcidid><orcidid>https://orcid.org/0000-0001-6150-1229</orcidid><orcidid>https://orcid.org/0000-0003-2574-3874</orcidid><orcidid>https://orcid.org/0000-0002-1631-5192</orcidid><orcidid>https://orcid.org/0000-0003-4553-3065</orcidid><orcidid>https://orcid.org/0000-0001-8772-0905</orcidid><orcidid>https://orcid.org/0000-0003-0111-7422</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-5555 |
| ispartof | Acta dermato-venereologica, 2017-03, Vol.97 (3), p.358-364 |
| issn | 0001-5555 1651-2057 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_01516926v1 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; IngentaConnect Free/Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adolescent Adult Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biopsy Cancer Child Child, Preschool Dermatology Disease Progression Female France Human health and pathology Humans Immunology Immunosuppressive Agents - adverse effects Immunosuppressive Agents - therapeutic use Immunotherapy Infant Life Sciences Lymphoma, T-Cell - drug therapy Lymphoma, T-Cell - immunology Lymphoma, T-Cell - mortality Lymphoma, T-Cell - pathology Male Middle Aged Panniculitis - drug therapy Panniculitis - immunology Panniculitis - mortality Panniculitis - pathology Proportional Hazards Models Remission Induction Retrospective Studies Time Factors Treatment Outcome Young Adult |
| title | Subcutaneous Panniculitis-like T-cell Lymphoma: Immunosuppressive Drugs Induce Better Response than Polychemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T20%3A39%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Subcutaneous%20Panniculitis-like%20T-cell%20Lymphoma:%20Immunosuppressive%20Drugs%20Induce%20Better%20Response%20than%20Polychemotherapy&rft.jtitle=Acta%20dermato-venereologica&rft.au=Michonneau,%20David&rft.date=2017-03-10&rft.volume=97&rft.issue=3&rft.spage=358&rft.epage=364&rft.pages=358-364&rft.issn=0001-5555&rft.eissn=1651-2057&rft_id=info:doi/10.2340/00015555-2543&rft_dat=%3Cproquest_hal_p%3E1835399838%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1835399838&rft_id=info:pmid/27722764&rfr_iscdi=true |